ZA941176B - Cognition-enhancing selective adenosine receptor agents - Google Patents

Cognition-enhancing selective adenosine receptor agents

Info

Publication number
ZA941176B
ZA941176B ZA941176A ZA941176A ZA941176B ZA 941176 B ZA941176 B ZA 941176B ZA 941176 A ZA941176 A ZA 941176A ZA 941176 A ZA941176 A ZA 941176A ZA 941176 B ZA941176 B ZA 941176B
Authority
ZA
South Africa
Prior art keywords
cognition
adenosine receptor
pct
selective adenosine
receptor agents
Prior art date
Application number
ZA941176A
Other languages
English (en)
Inventor
Janice M Hitchcock
Stephen M Sorensen
Mark W Dudley
Norton P Peet
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA941176B publication Critical patent/ZA941176B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA941176A 1993-02-26 1994-02-21 Cognition-enhancing selective adenosine receptor agents ZA941176B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26

Publications (1)

Publication Number Publication Date
ZA941176B true ZA941176B (en) 1994-09-20

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941176A ZA941176B (en) 1993-02-26 1994-02-21 Cognition-enhancing selective adenosine receptor agents

Country Status (19)

Country Link
US (1) US5840729A (fr)
EP (1) EP0686155B1 (fr)
JP (1) JPH08512281A (fr)
KR (1) KR100315898B1 (fr)
CN (1) CN1041418C (fr)
AT (1) ATE169019T1 (fr)
AU (1) AU680241B2 (fr)
CA (1) CA2155130C (fr)
DE (1) DE69412073T2 (fr)
DK (1) DK0686155T3 (fr)
ES (1) ES2120025T3 (fr)
HU (1) HUT72677A (fr)
IL (1) IL108750A (fr)
MX (1) MX9401406A (fr)
NO (1) NO311920B1 (fr)
NZ (1) NZ262984A (fr)
TW (1) TW261532B (fr)
WO (1) WO1994019349A1 (fr)
ZA (1) ZA941176B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041237A1 (fr) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Medicaments pour la prevention et la therapie de l'hyperphosphatemie
DZ2805A1 (fr) 1998-06-02 2005-01-30 Cadus Pharmaceutical Corp Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
CA2468673C (fr) 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Composes specifiques inhibant les recepteurs a1 et a3 de l'adenosine, et applications desdits composes
EA007468B1 (ru) 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
JP4414331B2 (ja) * 2002-05-15 2010-02-10 ジェンザイム、コーポレーション ベンゾニトリルおよびベンズイミデートの合成
WO2004086047A2 (fr) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1)
BRPI0417241A (pt) * 2003-12-09 2007-03-06 Kyowa Hakko Kogyo Kk agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (fr) * 2006-02-14 2007-08-23 New York University Méthodes et compositions pour traiter des troubles associés à une augmentation du renouvellement osseux et une ostéopénie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
DK0686155T3 (da) 1999-02-01
IL108750A0 (en) 1994-05-30
ATE169019T1 (de) 1998-08-15
AU680241B2 (en) 1997-07-24
CA2155130A1 (fr) 1994-09-01
IL108750A (en) 2000-09-28
CN1118599A (zh) 1996-03-13
KR100315898B1 (ko) 2002-02-28
DE69412073T2 (de) 1999-02-18
ES2120025T3 (es) 1998-10-16
EP0686155A1 (fr) 1995-12-13
NO311920B1 (no) 2002-02-18
HUT72677A (en) 1996-05-28
TW261532B (fr) 1995-11-01
NO953353L (no) 1995-08-25
DE69412073D1 (de) 1998-09-03
NZ262984A (en) 1997-05-26
MX9401406A (es) 1994-08-31
HU9502495D0 (en) 1995-10-30
CN1041418C (zh) 1998-12-30
US5840729A (en) 1998-11-24
AU6296894A (en) 1994-09-14
NO953353D0 (no) 1995-08-25
CA2155130C (fr) 1994-09-01
EP0686155B1 (fr) 1998-07-29
WO1994019349A1 (fr) 1994-09-01
JPH08512281A (ja) 1996-12-24

Similar Documents

Publication Publication Date Title
IL117848A0 (en) Novel compounds a process for their production and pharmacetical compositions containing same
EP0664792A4 (fr) Antagonistes des recepteurs du fibrinogene.
NO952229L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
DE69611377D1 (de) 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor
CA2094716A1 (fr) Dossier pour chaise ou siege
EP0509019A4 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
ZA946142B (en) Therapeutic heterocycles
TW261513B (fr)
ZA941176B (en) Cognition-enhancing selective adenosine receptor agents
TW283647B (fr)
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
DE68918944D1 (de) Künstliche rezeptor-analoge.
GR3005566T3 (fr)
GB9507883D0 (en) Compounds
SE9404438D0 (sv) New process
GR3024048T3 (en) Sugar derivatives of macrolides.
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
HU9500709D0 (en) Optically active hydroquinine (amino-3-phenyl)-1-ethanesulfonate, preparation and use thereof
NZ304823A (en) Beta carboline derivatives and medicaments
GR3027682T3 (en) 4-guanidinobutyramide for improving blood circulation.